化合物 T16870 T16870

Product Introduction
Bioactivity


英文名: Selgantolimod

描述: Selgantolimod is an effective and selective toll-like receptor 8 agonists for the treatment of the hepatitis B virus and human immunodeficiency virus infection.

体外活性: Selgantolimod induces the cellular immune mediators interleukin (IL)-12 and IL-8, as well as the antiviral cytokines tumor necrosis factor-α and interferon-γ in vitro in human peripheral blood mononuclear cells. Selgantolimod-induced cytokines reduce HBV DNA, RNA, and antigen levels in HBV-infected primary human hepatocytes. Selgantolimod activates natural killer and mucosal-associated invariant T cells, stimulates cluster of differentiation (CD)-8+ T-cell proliferation, and increase IFNγ production while lowering programmed cell death protein 1 expression by HBV-specific CD8+-T cells in vitro in peripheral blood mononuclear cells [1].

体内活性: Selgantolimod (p.o., once-weekly) treatment induces dose-dependent increases in serum IL-12 and IL-1 receptor antagonist (IL-1RA) in cynomolgus monkeys and causes functional cure in the woodchuck model of chronic HBV [1].

存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

关键字: Selgantolimod | GS 9688 | GS9688

相关产品: RO6889678 | Thiamine hydrochloride | Tenofovir Disoproxil Fumarate | Lagociclovir | NVR 3-778 | Doxorubicin hydrochloride | Clevudine | Mulberrofuran G | Adefovir dipivoxil | IR415

化合物 T16870 T16870信息由TargetMol中国为您提供，如您想了解更多关于化合物 T16870 T16870报价、型号、参数等信息，欢迎来电或留言咨询。

注：该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案，不可用于临床诊断或治疗等相关用途